Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company that develops and sells products for central nervous system (CNS) diseases. The company's neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Supernus Pharmaceuticals, Inc. is also developing new product candidates for CNS disorders. The company was incorporated in Delaware, started operations in 2005, and became publicly traded in 2012. Its shares are listed on the NASDAQ Stock Exchange under the ticker symbol SUPN. The principal executive offices are located in Rockville, Maryland. The company's product development expertise spans over 30 years, initially as a stand-alone development organization, then as a U.S. subsidiary of Shire Plc (a subsidiary of Takeda Pharmaceutical Company Ltd.), and since 2005, as Supernus Pharmaceuticals, Inc. following its acquisition of substantially all the assets of Shire Laboratories, Inc. On June 13, 2025, the company entered into a Merger Agreement to acquire Sage Therapeutics, Inc. (Sage). The company commenced a tender offer to acquire all outstanding shares of Sage at an offer price of $8.50 per share in cash (approximately $561 million paid as of the acquisition date), plus one contingent value right per share (approximately $234 million, subject to specific contingencies), representing the right to receive up to $3.50.